In most reported cases, previously-reported symptoms of candlenut were either general constitutional or gastrointestinal in nature.
1,6 Rarely, cases involving cardiac abnormalities have been reported,
3 including descriptions of bradycardia
5 and first-degree AV block.
1 One previous report from Spain in 2017
1 described a very similar case of a patient with elevated digoxin concentration after candlenut ingestion.
AV heart block occurs when there is a disruption in normal impulse conduction through the heart. Normal electrical conduction will begin at the sinoatrial (SA) node, disseminate throughout the atria, collect at the AV node, travel down to the bundle of His and the bundle branches, then propagate along the Purkinje fibers in the ventricles. Conduction failure can occur both at the AV node and infranodally. However, most Mobitz type II blocks in humans occur from infranodal disruption.
6 AV heart blocks can manifest from ischemia, drug toxicity, hyperkalemia, excessive vagal stimulation, cardiac valvular calcification, myocarditis, or infiltrative cardiomyopathy.
7,8
The mechanism by which the candlenut causes toxicity is largely unknown. However, phorbol esters are present in candlenuts, which can cause diarrhea, vomiting, and polyuria.
1 Phorbol esters also have cocarcinogenic effects, mimicking the action of diacylglycerol in the body, which then promotes protein kinase C (PKC) activity.
9 This increase of PKC activity in the presence of another carcinogen aids in promoting a tumor's growth. PKC activation is also responsible for some of the inflammatory effects of candlenut.
9 The etiology of heart blocks secondary to candlenut ingestion, however, remains enigmatic. A digoxin concentration measured on HD 2 in our patient was detectable, but the patient denied any exogenous cardioactive steroid exposure. Moreover, there was no suspicion of endogenous digoxin-like immunoreactive substances in this otherwise healthy patient. Plant-based cardioactive steroids can cross-react with digoxin assay, which assists in making a presumptive diagnosis of nonpharmaceutical cardioactive steroid exposure.
10-12 It is unknown whether candlenut exposure could, in fact, cause a falsely-elevated serum digoxin concentration. Potential adulterants in unregulated supplements could also cause the described adverse effects and toxicities. In this case, the presence of a detectable digoxin concentration may be indicative of a cardioactive steroid-based adulterant, contaminant, or component of the candlenut.
There are several limitations to a case study based on a patient's subjective report of what she may have ingested, including but not limited to a lack of reliability for the timing of ingestion, recall of exactly what was ingested, and other exact details of her recent history. There may also be a component of social desirability bias, as the patient may have been taking another medication or supplement that she did not report. Furthermore, we had no previous records of this patient to know what her baseline psychiatric or cardiac history may have been. She also did not bring a sample of the actual product to the hospital and we were unable to obtain it afterward. We do not know how the candlenut product was processed before it was ingested. There was also no expanded or confirmatory drug screening done at the hospital for this patient. Although absolute confirmation of exposure was impossible, the temporal relationship of symptom development abruptly after exposure to candlenut with cessation quickly thereafter, without any other obvious etiology, lend credence to candlenut toxicity. Though we cannot definitively claim causality, there seems to be an association with this patient's ingestion of candlenut supplement and her presentation.